Dados do Trabalho

Título

THE IMPACT OF THE 2022 WORLD HEALTH ORGANIZATION CLASSIFICATION OF RENAL TUMORS IN THE PRACTICE OF THE URO-PATHOLOGY-ONCOLOGY SERVICE OF A UNIVERSITY HOSPITAL

Introdução e Objetivo

The 2022 World Health Organization classification updated the group of “eosinophilic tumors”, including new entities that has emerged. Pathologists and uro-oncology groups have been challenged to adopt the new classification with further increment in the workflow for ancillary tests, reclassification of patients redefine treatment and follow-up. Thus, the objective of this study is to assess the impact of the new 2022 World Health Organization classification of renal tumors on the routine of an university hospital service.

Método

Retrospective review study of our institutional pathology database for renal cell tumors before and after the adoption of the 2022 World Health Organization Classification of Kidney Tumors. We retrieve 238 nefrectomy specimens and selected 42 cases with renal cell tumors including renal cell carcinomas and oncocytomas. Descriptive statistics were summarized as median and standard-deviation for continuous variables.

Resultados

An increase in the number of diagnosed eosinophilic renal tumors can be observed prior to immunohistochemistry (n=21, 9,52% pre-2022 classification and 23,81% post-2022 classification). Additionally, there has been also an increase in the frequency of immunohistochemical analyses performed within the service (n=21, 19,04% pre-2022 classification and 42,85% post-2022 classification). Furthermore, among these immunohistochemical analyses, there has been noticed an increase in the number of diagnosed chromophobe tumors following the new 2022 classification (n=4, 50,00% pre-2022 classification and n=9, 55,55% post-2022 classification).

Conclusão

The number of diagnosed eosinophilic tumors has increased, as well as the number of immunohistochemical analyses performed within the hospital service. Furthermore, there has been a significant impact on the quantity of diagnosed Chromophobe Renal Cell Carcinoma following immunohistochemistry, demonstrating that it has been diagnosed more frequently after the adoption of the new 2022 classification. Thus, urologists, pathologists and oncologists must be aware of the new classification paradigm and its impact in the final diagnosis of eosinophilic morphology tumors.